

APC anti-mouse TER-119/Erythroid Cells Antibody

Catalog# / Size	116211 / 25 µg 116212 / 100 µg
Clone	TER-119
Regulatory Status	RUO
Other Names	Ly-76
Isotype	Rat IgG2b, κ
Description	The TER-119 antigen is a 52 kD glycophorin A-associated protein, also known as Ly-76. TER-119 is an erythroid-specific antigen expressed on early proerythroblasts to mature erythrocytes, but not on erythroid colony-forming cells (BFU-E, blast-forming unit erythroid, or CFU-E, colony-forming unit erythroid).

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Day-14 fetal liver cells from a C57BL/6 mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	The TER-119 antibody is useful for distinguishing erythrocytes and cells in the erythroid lineage. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ , Western blotting ¹ , complement-mediated cytotoxicity ³ , and immunohistochemical staining of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections. Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 116253-116258).
Application References	<ol style="list-style-type: none">1. Kina T, <i>et al.</i> 2000. <i>Br. J. Haematol.</i> 109:280. (IP, WB)2. Vannucchi AM, <i>et al.</i> 2000. <i>Blood</i> 95:2559.3. Maraskovsky E, <i>et al.</i> 1996. <i>J. Exp. Med.</i> 184:1953. (CMCD)4. Grisendi S, <i>et al.</i> 2005. <i>Nature</i> 437:147. (FC)5. Bourdeau A, <i>et al.</i> 2007. <i>Blood</i> 109:4220.6. Chappaz S, <i>et al.</i> 2007. <i>Blood</i> 110:3862. (FC)7. Heuser M, <i>et al.</i> 2007. <i>Blood</i> 110:1639. (FC)8. Gough SM, <i>et al.</i> 2014. <i>Cancer Discov.</i> 4:564. PubMed
(PubMed link indicates BioLegend citation)	
Product Citations	<ol style="list-style-type: none">1. Yang D, <i>et al.</i> 2022. <i>Cell.</i> 185:1905. PubMed2. Koury D, <i>et al.</i> 2017. <i>Int J Parasitol.</i> 10.1016/j.ijpara.2017.05.009. PubMed3. Wang L, <i>et al.</i> 2018. <i>Bone Res.</i> 6:22. PubMed

4. DeSouza-Vieira T, *et al.* 2020. Cell Rep. 33:108317. [PubMed](#)
5. Symeonidou V, *et al.* 2021. Cell Rep. 37:109900. [PubMed](#)
6. Viny AD, *et al.* 2019. Cell Stem Cell. 25:682. [PubMed](#)
7. Ray S, *et al.* 2020. J Biol Chem. 295:7113. [PubMed](#)
8. Mourao L, *et al.* 2019. Sci Rep. 0.991666667. [PubMed](#)
9. Tanimura N *et al.* 2018. Developmental cell. 46(5):581-594 . [PubMed](#)
10. Chappaz S, *et al.* 2021. Cell Reports. 36(3):109430. [PubMed](#)
11. Yu VWC *et al.* 2016. Cell. 167(5):1310-1322 . [PubMed](#)
12. Li C, *et al.* 2021. Mol Ther. 29:822. [PubMed](#)
13. Engelbrecht E, *et al.* 2020. eLife. 9:e52690.. [PubMed](#)
14. Lutzmann M, *et al.* 2019. Cell Rep. 28:2851. [PubMed](#)
15. Yanagida K, *et al.* 2020. Dev Cell. 779:52. [PubMed](#)
16. Larouche JA, *et al.* 2021. eLife. 0.416666666666667. [PubMed](#)
17. Liu P, *et al.* 2020. Genome Res. 30:1655. [PubMed](#)
18. Nishina T, *et al.* 2021. Nat Commun. 12:2281. [PubMed](#)
19. Bilodeau M, *et al.* 2009. PLoS One. 4:e7500. [PubMed](#)
20. Dey A *et al.* 2019. The EMBO journal. 38(7) pii: e100293. [PubMed](#)
21. Yeo S, *et al.* 2016. Cancer Res . 76: 3397 - 3410. [PubMed](#)
22. Liu J, *et al.* 2012. PLoS One. 7:e44044. [PubMed](#)
23. Liu S, *et al.* 2021. Mol Ther. 29:1918. [PubMed](#)
24. Kunimoto H, *et al.* 2018. Cancer Cell. 33:44. [PubMed](#)
25. Parada-Kusz M, *et al.* 2018. Dis Model Mech. 11:. [PubMed](#)
26. Stivala S, *et al.* 2019. J Clin Invest. 130:1596. [PubMed](#)
27. Samarchith P Kurup *et al.* 2019. Cell host & microbe. 25(4):565-577 . [PubMed](#)
28. Riffelmacher T *et al.* 2017. Immunity. 47(3):466-480 . [PubMed](#)
29. Hillel-Karniel C, *et al.* 2020. Cell Reports. 30(3):807-819.e4.. [PubMed](#)
30. Lafkas D, *et al.* 2013. J Cell Biol. 203:47. [PubMed](#)
31. Haase C, *et al.* 2022. Nat Methods. 19:1622. [PubMed](#)
32. Negretti NM, *et al.* 2021. Development. 148:. [PubMed](#)
33. Shcherbina A, *et al.* 2020. Cell Rep. 32:107964. [PubMed](#)
34. Guihard S, *et al.* 2010. Blood. 115:3686. [PubMed](#)
35. Yu VWC, *et al.* 2017. Cell. 168:944. [PubMed](#)
36. Chen X *et al.* 2017. Cell stem cell. 21(6):747-760 . [PubMed](#)
37. Pal B, *et al.* 2017. Nat Commun.. 10.1038/s41467-017-01560-x. [PubMed](#)
38. Sá da Bandeira D, *et al.* 2022. Cell Rep. 40:111114. [PubMed](#)
39. Saleiro D, *et al.* 2022. Nat Commun. 13:1750. [PubMed](#)
40. Pezoldt J, *et al.* 2022. Nat Commun. 13:7227. [PubMed](#)
41. Nayak RR, *et al.* 2021. Cell Host Microbe. 29(3):362-377.e11. [PubMed](#)
42. Crowe JL, *et al.* 2020. Proc Natl Acad Sci U S A. 22953:117. [PubMed](#)
43. Perez E, *et al.* 2020. J Immunol. 205:2489. [PubMed](#)
44. Dagher T, *et al.* 2021. J Exp Med. 218: [PubMed](#)
45. Nosh S, *et al.* 2020. Int J Mol Sci. 21:00. [PubMed](#)
46. Kruta M, *et al.* 2021. Cell Stem Cell. . [PubMed](#)
47. Liu Z, *et al.* 2020. Cell. 178(6):1509-1525.e19.. [PubMed](#)
48. Shin JJ, *et al.* 2020. Cell Rep. 32:108093. [PubMed](#)
49. Long JT, *et al.* 2022. Elife. 11:. [PubMed](#)
50. Goldstein JM *et al.* 2019. Cell reports. 27(4):1254-1264 . [PubMed](#)
51. Li G, *et al.* 2020. J Clin Invest. 130:1233. [PubMed](#)
52. Hou Y, *et al.* 2021. Sci Transl Med. 13:. [PubMed](#)
53. Wang H, *et al.* 2019. J Clin Invest. 129:598. [PubMed](#)
54. Chen R, *et al.* 2021. Cell Reports. 34(7):108751. [PubMed](#)
55. Nahrendorf W, *et al.* 2021. eLife. 10:00. [PubMed](#)
56. Song J, *et al.* 2014. Exp Cell Res. 327:123. [PubMed](#)
57. Omatsu Y, *et al.* 2022. Nat Commun. 13:2654. [PubMed](#)
58. Maroni G, *et al.* 2019. Int J Mol Sci. 20. [PubMed](#)
59. Carmody C *et al.* 2019. Endocrinology. 160(5):1205-1222 . [PubMed](#)
60. Fu NY, *et al.* 2018. Dev Cell. 47:629. [PubMed](#)
61. Siddique SM, *et al.* 2019. Sci Rep. 9:13977. [PubMed](#)
62. Yeo SK, *et al.* 2020. eLife. 9:e58810.. [PubMed](#)
63. Ma L, *et al.* 2022. Sci Adv. 8:eabm3470. [PubMed](#)
64. Chen C, *et al.* 2020. Cell Rep. 2136:30. [PubMed](#)
65. Maeda K, *et al.* 2021. Pathogens. 10:. [PubMed](#)
66. Magee JA, *et al.* 2021. Stem Cell Reports. 16:20. [PubMed](#)
67. Rai S, *et al.* 2022. Nat Commun. 13:5346. [PubMed](#)
68. Cambridge E, *et al.* 2017. Exp Hematol. 45:64-68.e5. [PubMed](#)
69. Markworth JF, *et al.* 2020. JCI Insight. 5:00. [PubMed](#)
70. Wang H, *et al.* 2020. JCI Insight. 5:00. [PubMed](#)
71. Pal B, *et al.* 2021. Breast Cancer Res. 23:69. [PubMed](#)
72. Maller O, *et al.* 2020. Nat Mater. 20:548. [PubMed](#)
73. Woods B, *et al.* 2019. Clin Cancer Res. 25:5901. [PubMed](#)
74. Hidalgo San Jose L, *et al.* 2020. Cell Rep. 30:69. [PubMed](#)
75. Khoriaty R, *et al.* 2014. Mol Cell Biol. 34:3721. [PubMed](#)
76. Awida Z, *et al.* 2021. Int J Mol Sci. 23:. [PubMed](#)
77. Koyama M *et al.* 2019. Immunity. 51(5):885-898 . [PubMed](#)
78. Yin Y, *et al.* 2016. J Biol Chem. 291: 6923 - 6935. [PubMed](#)
79. Rowe R, *et al.* 2016. J Exp Med. 213: 1497 - 1512. [PubMed](#)
80. Werner MT, *et al.* 2020. J Biol Chem. 295:1898. [PubMed](#)
81. Schmidts A, *et al.* 2020. J Immunother Cancer. 8:. [PubMed](#)
82. Murray CW, *et al.* 2022. Nat Commun. 13:1090. [PubMed](#)
83. Lam J, *et al.* 2018. Nat Commun. 9:2418. [PubMed](#)

RRID

AB_313712 (BioLegend Cat. No. 116211)
AB_313713 (BioLegend Cat. No. 116212)

Antigen Details

Structure	Associated with glycophorin A, 52 kD
Distribution	Early proerythroblast to mature erythrocyte, but not BFU-E and CFU-E
Cell Type	Erythrocytes
Biology Area	Immunology
Antigen References	1. Kina T, <i>et al.</i> 2000. <i>Br. J. Haematol.</i> 109:280. 2. Ikuta K, <i>et al.</i> 1990. <i>Cell</i> 62:863. 3. Osawa M, <i>et al.</i> 1996. <i>Weir's Handbook of Experimental Immunology</i> . Vol. 2 pp. 66.1-66.5.
Gene ID	104231


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse TER-119/Erythroid Cells, Biotin anti-mouse TER-119/Erythroid Cells, FITC anti-mouse TER-119/Erythroid Cells, PE anti-mouse TER-119/Erythroid Cells, PE/Cyanine5 anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 488 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 647 anti-mouse TER-119/Erythroid Cells, Alexa Fluor® 700 anti-mouse TER-119/Erythroid Cells, PE/Cyanine7 anti-mouse TER-119/Erythroid Cells, APC/Cyanine7 anti-mouse TER-119/Erythroid Cells, PerCP anti-mouse TER-119/Erythroid Cells, PerCP/Cyanine5.5 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 421™ anti-mouse TER-119/Erythroid Cells, Pacific Blue™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 650™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 510™ anti-mouse TER-119/Erythroid Cells, Brilliant Violet 605™ anti-mouse TER-119/Erythroid Cells, Purified anti-mouse TER-119/Erythroid Cells (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse TER-119/Erythroid Cells, Brilliant Violet 785™ anti-mouse TER-119/Erythroid Cells, TotalSeq™-A0122 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 750 anti-mouse TER-119/Erythroid Cells, TotalSeq™-B0122 anti-mouse TER-119/Erythroid Cells, TotalSeq™-C0122 anti-mouse TER-119/Erythroid Cells, Ultra-LEAF™ Purified anti-mouse TER-119/Erythroid Cells, Spark Blue™ 550 anti-mouse TER-119/Erythroid Cells, APC/Fire™ 810 anti-mouse TER-119/Erythroid Cells, Spark NIR™ 685 anti-mouse TER-119/Erythroid Cells Antibody

Product Data



C57BL/6 bone marrow cells stained with TER-119 APC and anti-mouse CD45 FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587